Comprehensive omic characterization of breast cancer in Mexican-Hispanic women.
Nature Communications
Romero-Cordoba, Sandra L SL; Salido-Guadarrama, Ivan I; Rebollar-Vega, Rosa R; Bautista-Piña, Veronica V; Dominguez-Reyes, Carlos C; Tenorio-Torres, Alberto A; Villegas-Carlos, Felipe F; Fernández-López, Juan C JC; Uribe-Figueroa, Laura L; Alfaro-Ruiz, Luis L; Hidalgo-Miranda, Alfredo A
Formalin fixation increases deamination mutation signature but should not lead to false positive mutations in clinical practice.
Plos One
Prentice, Leah M LM; Miller, Ruth R RR; Knaggs, Jeff J; Mazloomian, Alborz A; Aguirre Hernandez, Rosalia R; Franchini, Patrick P; Parsa, Kourosh K; Tessier-Cloutier, Basile B; Lapuk, Anna A; Huntsman, David D; Schaeffer, David F DF; Sheffield, Brandon S BS
MEK inhibitors overcome resistance to BET inhibition across a number of solid and hematologic cancers.
Oncogenesis
Wyce, Anastasia A; Matteo, Jeanne J JJ; Foley, Shawn W SW; Felitsky, Daniel J DJ; Rajapurkar, Satyajit R SR; Zhang, Xi-Ping XP; Musso, Melissa C MC; Korenchuk, Susan S; Karpinich, Natalie O NO; Keenan, Kathryn M KM; Stern, Melissa M; Mathew, Lijoy K LK; McHugh, Charles F CF; McCabe, Michael T MT; Tummino, Peter J PJ; Kruger, Ryan G RG; Carpenter, Christopher C; Barbash, Olena O
LowMACA: exploiting protein family analysis for the identification of rare driver mutations in cancer.
Bmc Bioinformatics
Melloni, Giorgio E M GE; de Pretis, Stefano S; Riva, Laura L; Pelizzola, Mattia M; Céol, Arnaud A; Costanza, Jole J; Müller, Heiko H; Zammataro, Luca L